bcl-2癌基因蛋白在甲状腺癌中的表达及其意义

利用免疫组织化学技术,对６４例甲状腺癌进行了ｂｃｌ－２蛋白表达的检测,同时进行ｐ５３蛋白的对照检测。结果显示,甲状腺癌中ｂｃｌ－２蛋白阳性表达率为８１．３％（５２／６４）,但未分化癌无阳性表达。ｐ５３蛋白在甲状腺癌的阳性表达率为２０．３％（１３／６４）,而未分化癌全部为阳性表达。两种抗体在甲状腺癌的阳性表达率有显著性差异（Ｐ＜０．０１）。结果提示ｂｃｌ－２蛋白在甲状腺癌的表达与肿瘤细胞的分化程度有关,并与ｐ５３蛋白呈反比关系,ｂｃｌ－２与ｐ５３蛋白表达的不同分布可作为判断甲状腺癌预后的一个重要参考指标     

p53突变蛋白在胃癌组织中的表达及免疫电镜观察

作者应用抗ｐ５３单克隆抗体Ｐａｂ１８０１（Ａｂ２美国癌基因公司产品）对３８例手术切除的胃癌组织及癌旁胃粘膜的冰冻切片标本进行ｐ５３突变蛋白表达的检测,并进一步用胶体全免疫电镜技术对ｐ５３突变蛋白的分布特征进行观察。结果：３８例胃癌组织中,２４例有ｐ５３突变蛋白高表达,阳性率６３．２％。在对应的癌旁胃粘膜中１０例为ｐ５３的弱表达,正常组织无表达。伴有淋巴结转移的２３例胃癌标本中,１８例ｐ５３高表达（７８．３％）。免疫电镜结果表现,ｐ５３蛋白主要分布于核内染色质中,胞浆中有散在的阳性区,但以核膜周边为主,紧靠核膜。本研究结果提承胃癌的发生及其肿瘤的生物学行为与抑癌基因ｐ５３的突变密切相关,ｐ５３突变蛋白可能是通过对ＤＮＡ复制的影响而参与肿瘤的形成。     

蛋白激酶底物p36在肝硬变、肝细胞肝癌中的表达及与HBV、HCV感染的关系

本文应用鼠抗蛋白激酶底物ｐ３６单克隆抗体,采用免疫组织化学法对ｐ３６在５４例肝硬变,７９例肝细胞肝癌中的表达分布进行了研究,同时结合ＨＢＶ、ＨＣＶ感染情况分析其相互关系,结果显示：ｐ３６在肝硬变及肝细胞肝癌中定位于肝细胞或癌细胞胞浆内,在胞浆内弥漫分布,阳性细胞呈灶状或弥漫分布,部分病例癌周肝细胞信号较癌组织为强,ｐ３６在肝硬变、肝细胞癌中的阳性率分别为８８．８％（４８／５４）及８２．３（６５／７９）,ＨＢｘＡｇ在两种组织的阳性率分别为７０．４％及７６％,ＨＣＶ核心抗原在两种组织的阳性率分别为８０％及７８．５％;三者同时阳性分别为５５．５％及５８．２％;ｐ３６、ＨＢｘＡｇ同时阳性分别为６８．５％及６４．５％;ｐ３６、核心抗原同时阳性分别为７４．１％及７０．８％,我们的结果提示,肝硬变、肝细胞肝癌组织中ｐ３６存在高表达,其高表达可能与ＨＢＶ、ＨＣＶ感染密切相关     

大鼠肝癌发生过程中p53的突变和甲胎蛋白的表达

采用免疫组织化学ＡＢＣ和ＰＡＰ法,对二乙基亚硝胺（ＤＥＮ）诱发大鼠肝癌发生过程中突变型ｐ５３蛋白（ｍｐ５３）和甲胎蛋白（ＡＦＰ）在肝细胞中的表达进行了系统观察。结果显示：（１）ＤＥＮ诱发大鼠肝癌发生率为１００％;（２）正常大鼠及诱癌第４周大鼠的肝细胞均不表达ｍｐ５３,至诱癌第８周,可见少量肝细胞表达ｍｐ５３,诱癌晚期的癌结节内大部分肝癌细胞呈ｍｐ５３阳性表达,ｍｐ５３免疫反应阳性产物为胞核内棕褐色颗粒;（３）正常大鼠肝细胞不表达ＡＦＰ,诱癌早期（４～８周）的大鼠肝小叶内可见少量ＡＦＰ阳性肝细胞,多为小肝细胞,呈散在分布,此后ＡＦＰ阳性肝细胞逐渐增多,晚期的癌结节内大部分癌细胞呈ＡＦＰ阳性,ＡＦＰ免疫反应阳性产物为胞浆内棕褐色颗粒。结果提示,ｍｐ５３和ＡＦＰ可作为分析肝癌进展的病理学指标     

nm23-H_1基因在乳腺癌的表达及其与p16基因表达的相关性研究

用ＬＳＡＢ免疫组织化学技术,检测了ｎｍ２３－Ｈ１基因在乳腺癌的表达情况。在１４３例乳腺癌中,７６．２％呈阳性表达。ｎｍ２３－Ｈ１基因表达与患者年龄、肿瘤大小、组织学分类、分级,雌、孕激素受体状态以及ｐ１６基因表达无明显相关（Ｐ＞０．０５）;但淋巴结转移组阳性率６４．１％（４１／６４）显著低于无转移组８３．９％（５２／６２）（Ｐ＜０．０５）,ｎｍ２３－Ｈ１阳性表达组的死亡率３５．７％（１０／２８）,也明显低于阴性组５５．６％（５／９）,提示检测ｎｍ２３－Ｈ１蛋白可能成为乳腺癌患者的一种新的预后指标。ｎｍ２３－Ｈ１和ｐ１６基因表达无明显相关性,提示二者可能通过两种不同的机制和途径影响癌转移和预后,联合检测此二种蛋白对判断乳腺癌患者的癌转移和预后更有临床意义。     

CD15、溶菌酶和p53的表达及其与大肠癌浸润转移的关系

应用免疫组织化学ＳＰ法检测了９０ 例大肠癌组织中ＣＤ１５、溶菌酶（ＬＺＭ） 和ｐ５３ 的表达。结果显示大肠癌中ＣＤ１５、ＬＺＭ 和ｐ５３ 表达阳性率分别为８３．３％ 、７０．０％ 和５７．８％ 。ＣＤ１５ 表达与大肠癌的组织类型和ＬＺＭ 表达无关。ＬＺＭ 和ｐ５３ 表达与大肠癌组织类型有关（Ｐ＜ ０．０５）。ｐ５３ 表达与ＣＤ１５ 和ＬＺＭ 表达相关（Ｐ＜ ０．００１）。ＣＤ１５、ＬＺＭ 和ｐ５３表达均与大肠癌的浸润和转移相关（Ｐ＜ ０．０５）。本文揭示ＣＤ１５、ＬＺＭ和ｐ５３在大肠癌的发生发展、浸润和转移过程中具有独立或相互影响作用, 其相互作用机制有待深入研究。因此认为联合检测ＣＤ１５、ＬＺＭ 和ｐ５３表达状况, 是判断大肠癌分化程度、浸润、转移和预测预后的良好指标。同时也为利用不同基因变化研究大肠癌的发病机制、探讨治疗和预防提供一种新途径。     

乳腺癌p53蛋白过度表达和雌激素受体免疫组化检测及意义

应用免疫组化方法,对３２例乳腺癌组织中肿瘤抑制基因ｐ５３蛋白的表达和雌激素受体的状态分别进行了检测。结果３２例中ｐ５３蛋白阳性１８例,阳性率５６．３％,１８例伴有同侧腋下淋巴结转移者阳性１３例（７２．２％）３而１４例无转移者阳性５例（３５．７％）二组阳性率差异显著（ＰＭＯ．０５）。３２例中雌激素受体阳性１７例,１８例伴转移者阳性８例（４４．４％）;１４例无转移者阳性９例（６４．３％）。结果表明,ｐ５３蛋白的异常表达与乳腺癌的浸润转移有关,结合雌激素受体的检查,可作为临床预后判断一个有价值的标志。     

乳腺癌HSV—1,HSV—2与c—erbB—2的免疫组化研究

采用免疫组织化学Ｓ－Ｐ法检测５２例手术切除乳腺癌组织ｃ－ｅｒｂＢ－２蛋白和ＨＳＶ－１、ＨＳＶ－２表达情况。结果发现癌组织中ｃ－ｅｒｂＢ－２阳性３４例（６５．４％）;ＨＳＶ－１阳性３８例（７３．１％）;ＨＳＶ－２阳性１５例（２８．８％）。癌旁组织３２例,阳性分别为３例（９．４％）;１２例（３７．５％）;２例（６．３％）。乳腺癌中ｃ－ｅｒｂＢ－２阳性率明显高于癌旁组织。乳腺癌及癌旁的ＨＳＶ－１阳性率明显高于ＨＳＶ－２,乳腺癌ｃ－ｅｒｂＢ－２阳性组中ＨＳＶ－１和ＨＳＶ－２的表达有显著差异,而在阴性组二者无差异,提示乳腺癌的发生可能和ＨＳＶ－１感染密切相关,ｃ－ｅｒｂＢ－２表达也可能和ＨＳＶ－１感染有关。     

在HBV感染的肝癌组织中Fas/FasL表达的作用

目的探讨Fas／FasL（Fas配体）在原发性肝细胞肝癌（HCC）组织中的表达及其与乙肝病毒（HBV）感染的关系。方法用免疫组化S-P法检测21例肝癌组织及其10例癌旁组织Fas／FasL的表达。结果在肝癌和癌旁组织中Fas表达的阳性率分别为52．38％和80．00％（P〈0．05）,FasL分别为66．67％和40．00％（P〈0．05）。在HBsAg阳性和阴性组Fas表达的阳性率分别为50．00％和66．67％（P〉0．05）;FasL分别为61．11％和100％（P〈0．05）。肝癌组织中Fas、FasL表达与性别、年龄、肿瘤大小无关,与癌栓转移呈负相关,FasL与分化程度有关。结论肝癌细胞能下调Fas及上调FasL的表达而使凋亡受阻,HBV感染能抑制肝癌组织FasL的表达,可能是HBV在HCC的发牛及发展讨稃中的致痛机制。     

P53和PCNA的表达与大肠癌关系的免疫组织化学研究

本研究采用免疫组织细胞化学ＡＢＣ法对６２例大肠癌区、癌移行区及癌旁区组织内Ｐ５３和ＰＣＮＡ蛋白进行检测。结果表明,Ｐ５３蛋白在大肠癌区阳性率占６１．３％（３８／６２）、ＰＣＮＡ蛋白阳性率占７１．０％（４４／６２）、阳性结果均位于癌细胞核内,Ｐ５３蛋白阳性的癌细胞,少部分为核浆型。Ｐ５３及ＰＣＮＡ蛋白联合表达与大肠癌发生及发展相关密切,并互相协同致癌,对大肠癌分化程度和Ｄｕｋｅｓ分期影响较大,为大肠癌病变研究提供了分子生物学信息,对手术切除缘范围和评估大肠癌转移和预后有一定参考价值。     

Genetic aberration in primary hepatocellular carcinoma：correlation between p53 gene mutation and loss—of—heterozygosity on chromosome 16q21—q23 and 9p21—p23

To elucidate the molecular pathology underlying the development of hepatocellular carcinoma (HCC),we used 41 highly polymorphic microsatellite markers to examine 55 HCC and corresponding non-tumor liver tissues on chromosome 9,16 and 17.Loss-of-heterozygosity(LOH) is observed with high frequency on chromosomal region 17p13(36k/55,65%),9q21-p23(28/55,51%),16q21-23(27/55,49%) in tumors.Meanwhile,microsatellite instability is rarely found in these microsatellite loci.Direct sequencing was performed to detect the tentative mutation of tumor wuppressor genes in these regions:p53,MTS1/p16,and CDH1/E-cadherin.Wihin exon 5-9 of p53 gene,14 out of 55 HCC specimens(24%) have somatic mutations,and nucleotide deletion of this gene is reported in HCC for the first time.Mutation in MTS1/p16 is found only in one tumor case.We do not find mutations in CDH1/E-cadherin.Furthermore,a statistically significant correlation is present between p53 gene mutation and loss of chromosome region 16q21-q23 and 9p21-p23,which indicates that synergism between p53 inactivation and deletion of 16q21-q23 and 9p21-p23 may play a role in the pathogenesis of HCC.     

Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma

 Mutated p53 proteins accumulate in the nuclei of tumor cells, and anti-p53 autoantibodies are found in the sera of patients with non-small-cell lung carcinoma (NSCLC). We analyzed the correlation among serum anti-p53 autoantibodies, immunohistochemical staining for p53, and clinical features (age, gender, smoking history, histological type, differentiation, stage, T factor, tumor size, and N factor) in resected non-small-cell lung carcinomas. A total of 62 cases of resected NSCLC were studied (43 men and 19 women; 33 adenocarcinomas, 21 squamous cell carcinomas, 8 large-cell carcinomas). Preoperative serum titers of anti-p53 autoantibodies were detected in 13/62 cases (21.0%). A correlation between histological type and positive titers of serum p53 autoantibodies was seen (large-cell carcinoma versus squamous cell carcinoma and adenocarcinoma, P = 0.031, χ²-test). Out of 25 cases, 10 (40%) with positive immunohistochemical staining for p53 had positive titers, whereas 3 positive titers were found in 37 patients with negative immunohistochemical staining for p53 (P = 0.0025, χ²-test). Serum titers of anti-p53 autoantibodies were present in approximately 20% of the cases of NSCLC, and overexpression of p53 protein in tumor cells was detectable in approximately 40%. Serum anti-p53 autoantibodies may be a clinical parameter for the presence of p53 mutations and p53 overexpression in NSCLC patients. Received: 22 October 1997 / Accepted: 22 April 1998     

Downregulation of proapoptotic proteins Bax and Bcl-X(S) in p53 overexpressing hepatocellular carcinomas

As the occurrence of structural p53 mutations in hepatocellular carcinoma (HCC) in Thailand was previously reported to be much lower than that found in other high-incidence HCC areas, we analyzed 16 HCC samples from Thailand to determine the expression and functionality of p53 protein. We observed the overexpression of p53 protein in 69% of HCC, despite the prevalence of the wild-type p53 gene. However, the overexpressed p53 protein was nonfunctional as suggested by its inability to modulate the expressions of several p53 effector proteins (p21 and Bcl-2 family proteins). In addition, we observed significant underexpression of two proapoptotic proteins, Bax and Bcl-X(S), in 81% (P = 0.02) and 64% (P = 0.03) of HCC, respectively. Consequently, the ratios of proapoptotic to antiapoptotic BCL-2 family proteins were reduced in 88% of the HCC tumor tissues when compared to normal tissues, such that the rheostat between BCL-2 family proteins is strongly skewed toward enhanced cell survival in the tumor cells.     

P~（53） PROTEIN OVEREXPRESSION IN PREMALIGNANT AND MALIGNANT LESIONS OF ORAL MUCOSA：IMMUNOHISTOCHEMICAL OBSERVATION

Ｐ~（５３）　ＰＲＯＴＥＩＮ　ＯＶＥＲＥＸＰＲＥＳＳＩＯＮ　ＩＮ　ＰＲＥＭＡＬＩＧＮＡＮＴ　ＡＮＤ　ＭＡＬＩＧＮＡＮＴ　ＬＥＳＩＯＮＳ　ＯＦ　ＯＲＡＬ　ＭＵＣＯＳＡ：ＩＭＭＵＮＯＨＩＳＴＯＣＨＥＭＩＣＡＬ　ＯＢＳＥＲＶＡＴＩＯＮＰ~（５３）ＰＲＯＴＥＩ...     

Prostaglandin E2 stimulates p53 transactivational activity through specific serine 15 phosphorylation in human synovial fibroblasts. Role in suppression of c/EBP/NF-kappaB-mediated MEKK1-induced MMP-1 expression

Cyclooxygenase-2 (COX-2) overexpression has been linked to cell survival, transformation, and hyperproliferation. We examined the regulation of the tumor suppressor gene p53 and p53 target genes by prostaglandin E(2) (PGE(2)) in human synovial fibroblasts (HSF). PGE(2) induced a time-dependent increase in p53 Ser(15) phosphorylation, with no discernible change in overall p53 levels. PGE(2)-dependent Ser(15) phosphorylation was apparently mediated by activated p38 MAP kinase as SB202190, a p38 kinase inhibitor, blocked the response. Overexpression of a MKK3 construct, but not MKK1, stimulated SB202190-sensitive p53 Ser(15) phosphorylation. PGE(2)-stimulated [phospho-Ser(15)]p53 transactivated a p53 response element (GADD45)-luciferase reporter in transiently transfected HSF (SN7); the effect was compromised by overexpression of a dominant-negative mutant (dnm) of p53 or excess p53S15A expression plasmid but mimicked by a constitutively active p53S15E expression construct. PGE(2), wtp53 expression in the presence of PGE(2), and p53S15E suppressed steady-state levels of MEKK1-induced MMP-1 mRNA, effects nullified with co-transfection of p53 dnm or p53S15A. MEKK1-induced MMP-1 promoter-driven luciferase activity was largely dependent on a c/EBPbeta-NF-kappaB-like enhancer site at -2008 to -1972 bp, as judged by deletion and point mutation analyses. PGE(2), overexpression of p53wt with PGE(2), or p53S15E abolished the MEKK1-induced MMP-1 promoter luciferase activity. Gel-shift/super gel-shift analyses identified c/EBPbeta dimers and c/EBPbeta/NF-kappaB p65 heterodimers as binding species at the apparent site of MEKK1-dependent transactivation. PGE(2)-stimulated [phospho-Ser(15)]p53 abrogated the DNA binding of c/EBPbeta dimers and c/EBPbeta/NF-kappaB p65 heterodimers. Our data suggest that COX-2 prostaglandins may be implicated in p53 function and p53 target gene expression.     

p53 Promotes proteasome-dependent degradation of oncogenic protein HBx by transcription of MDM2

Hepatitis B virus X protein (HBx) is closely involved in the development of hepatocellular carcinoma (HCC). Tumor suppressor p53 was reported to induce HBx degradation and repress its oncogenic function recently, but the molecular mechanism is unknown. In this study, we attempted to identify the underlying mechanism. We found that overexpression of p53 protein reduces the level of HBx protein and shortens its half-life, however, in MDM2 knock out cells, p53 has no effects on degradation of HBx, meanwhile, overexpression of MDM2 in absence of p53 can accelerate turnover of HBx protein. These indicate that p53-mediated HBx degradation is MDM2-dependent. MDM2 interacts with HBx in vitro and in vivo but does not promote its ubiquitination. In consistent with the results above, HCC tissue samples with wild-type p53 hardly detect HBx protein, whereas, HBx always accumulate in the tissues with mutant p53. Our data provide a possible mechanism on how p53 regulate HBx stability and also a new clue for the study of p53 mutation and HCC development.     

Overexpression of p53 protein is not directly related to hepatitis B x protein expression and is associated with neoplastic progression in hepatocellular carcinomas rather than hepatic preneoplasia

p53 mutations and binding of p53 to hepatitis B virus (HBV) x protein (HBx) have been suggested as alternative mechanisms of development of hepatocellular carcinomas (HCCs) in man, both processes resulting in intracellular accumulation of the protein which is detectable by immunohistochemical approaches. We have examined p53 expression in 149 explanted human livers, including 39 cases infected with HBV and 35 bearing HCC. p53 was demonstrated immunohistochemically in 51% of HCC samples (18/35), localized mainly in fast growing poorly differentiated areas. Accumulation of mutant p53 was verified by immunoprecipitation in most of the positive HCC samples (14/15), implying occurrence of p53 mutations. No cells positive for p53 were found in 354 preneoplastic hepatocellular lesions examined. This indicates that p53 mutation is associated with progression, rather than early development, of HCC in the low-aflatoxin B(1)-exposed region. The intracellular distribution patterns of p53 and HBx were different, with the former within nuclei and the latter confined to cytoplasmic compartment. HBx did not coimmunoprecipitate with p53. These data indicate that p53-HBx binding is infrequent, if it really occurs, in HBV-infected human liver, and that it cannot be a common mechanism of HBV-associated hepatocarcinogenesis. In addition, p53 accumulation was also observed in some parenchymal and ductular (oval) cells in cirrhotic livers and, more frequently, in fulminant hepatitis, being independent of HBx expression, and seemingly associated with the damage and/or regeneration of liver parenchyma, perhaps merely reflecting a cellular stress response.     

Investigation of oncogene amplification or deletion,and oncoprotein expression in papillary thyroid cancer

AIM: Assessment of occurrence and possible prognostic significance of c-myc and Ha-ras amplification, p53 deletion and overexpression of cyclin D1, p53 and p21 in papillary thyroid cancer. MATERIALS AND METHODS: Formalin-fixed, paraffin-embedded tumor tissue from 24 patients were investigated. Dot-blot DNA hybridization was used to detect oncogene amplification or deletion. The expression of oncoproteins was determined by immunohistochemical method. RESULTS: In our samples neither Ha-ras amplification nor p53 deletion were found. Low c-myc amplification (mean: 2.55) occured in 4 cases (17%). p53 protein was detected in 16 samples (66.6%), with p21 expression (chi(2)=7.02, p<0.01) in 6 cases (25%). The p53 expression did not influence the tumor fenotype. Cyclin D1 overexpression was found in 12 cases (50%), it was often associated with p21 expression (chi2=10.1, p<0.001) and in inverse relation to the tumor lymphocytic infiltration (chi(2)=5.35, p<0.05). Increased expression of estrogen receptor was shown in 4 cyclin D1 positive samples (17%). CONCLUSIONS: The p53 detected in our study is likely not to be mutant protein in all cases because its presence was associated with p21 expression that the mutant protein cannot induce and also it did not mean more aggressive tumor phenotype. The connection of cyclin D1 overexpression with the lymphocytic infiltration of the tumor suggests that the increased expression of cyclin D1 means poor prognosis. The coexpression of cyclin D1 and p21 raises the modulative character of the p21 protein, thought to be a tumor suppressor originally, but we find a CDK-independent, estrogen receptor mediated effect of cyclin D1 more likely, which has been described in breast cancer and is also proved by the coexpression of cyclin D1 and estrogen receptor detected here.